Association of serum sex hormones with hemostatic factors in women on and off hormone therapy: The multiethnic study of atherosclerosis

Journal of Women's Health

Volumn 25, Issue 2, 2016, Pages 166-172

  Williams, Marlene S ^a   Cushman, Mary ^b   Ouyang, Pamela ^a   Heckbert, Susan R ^c   Kalyani, Rita Rastogi ^a   Vaidya, Dhanajay ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; ESTRADIOL; ESTROGEN; FIBRINOGEN; GESTAGEN; HOMOCYSTEINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRASTERONE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; HEMOSTATIC AGENT; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEMOSTASIS; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; THROMBOSIS; AGED; BLOOD; EPIDEMIOLOGY; ESTROGEN THERAPY; ETHNOLOGY; MIDDLE AGED; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BIOMARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DEHYDROEPIANDROSTERONE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; GONADAL STEROID HORMONES; HEMOSTATICS; HUMANS; LIPOPROTEINS; LONGITUDINAL STUDIES; MIDDLE AGED; POSTMENOPAUSE; SEX HORMONE-BINDING GLOBULIN; UNITED STATES;

EID: 84958676406     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2015.5465     Document Type: Article

References (38)

1. Ushioda M, Makita K, Takamatsu K, Horiguchi F, Aoki D. Serum lipoprotein(a) dynamics before/after menopause and long-Term effects of hormone replacement therapy on lipoprotein( a) levels in middle-Aged and older Japanese women. Horm Metab Res. 2006; 38: 581-586.
2. Ayres S, Abplanalp W, Liu JH, Subbiah MTR. Mechanisms involved in the protective effect of estradiol-17b on lipid peroxidation and DNA damage. American Journal of Physiology-Endocrinology and Metabolism. 1998; 274: E1002-E1008.
3. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. American Journal of Physiology, Regulatory, Integrative and Comparitive Physiology. 2004; 286: R233-49.
4. Canonico M. Hormone therapy and hemostasis among postmenopausal women: A review. Menopause. 2014; 21: 753-762.
5. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985; 313: 1044-1049.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-333.
7. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: Scientific review. JAMA. 2002; 288: 872-881.
8. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA. 2004; 291: 1701-1712.
9. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003; 362: 428-432.
10. Lowe GD, Upton MN, Rumley A, McConnachie A, O'Reilly DS, Watt GC. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein-A cross-sectional population survey. Thromb Haemost. 2001; 86: 550-556.
11. Rossouw JE, Cushman M, Greenland P, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. Arch Intern Med. 2008; 168: 2245-2253.
12. Kooperberg C, Cushman M, Hsia J, et al. Can biomarkers identify women at increased stroke risk?TheWomen'sHealth Initiative Hormone Trials. PLoS Clin Trials. 2007; 2: e28.
13. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999; 100: 717-722.
14. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/.progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women A randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997; 17: 3071-3078.
15. Manson J. Presidential symposium: Plenary symposium #1: New findings from the Kronos Early Estrogen Prevention Study (KEEPS) randomized trial. In: North American Menopause Society 23rd Annual Meeting, 2012; 2012.
16. Bild DE, Bluemke DA, Burke GL, et al. Multi-Ethnic Study of Atherosclerosis: Objectives and design. Am J Epidemiol. 2002; 156: 871-881.
17. Ouyang P, Vaidya D, Dobs A, et al. Sex hormone levels and subclinical atherosclerosis in postmenopausal women: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2009; 204: 255-261.
18. Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 1988; 71: 220-225.
19. Stomati M, Hartmann B, Spinetti A, et al. Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women. J Endocrinol Invest. 1996; 19: 535-541.
20. Waaseth M, Bakken K, Dumeaux V, et al. Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer postgenome cohort- A cross-sectional analysis. BMC Womens Health. 2008; 8: 1.
21. Hoibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism-Results from a randomized, double-blind, clinical trial. Thromb Haemost. 2001; 85: 775-781.
22. Sandset PM, Hoibraaten E, Eilertsen AL, Dahm A. Mechanisms of thrombosis related to hormone therapy. Thromb Res. 2009; 123 Suppl 2: S70-S73.
23. Bowden DW, Lohman K, Hsu FC, et al. Hormone replacement therapy is associated with increased C-reactive protein in women with Type 2 diabetes in the Diabetes Heart Study. Diabet Med. 2006; 23: 763-767.
24. Raps M, Helmerhorst FM, Fleischer K, et al. The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI. Thromb Haemost. 2013; 109: 606-613.
25. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: Structure, biology and involvement in disease. J Pathol. 2006; 208: 327-339.
26. Dahm A, van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003: 4387-4392.
27. Raps M, Helmerhorst F, Fleischer K, et al. Sex hormonebinding globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost. 2012; 10: 992-997.
28. Stegeman BH, Raps M, Helmerhorst FM, et al. Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on plasma sex hormone-binding globulin levels in premenopausal women. J Thromb Haemost. 2013; 11: 203-205.
29. Rossouw JE, Johnson KC, Pettinger M, et al. Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy. Stroke. 2012; 43: 952-957.
30. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003; 349: 523-534.
31. Ford ES, Giles WH, Mokdad AH, Myers GL. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem. 2004; 50: 574-581.
32. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135-1143.
33. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease-Prospective analysis from the Women's Health Initiative observational study. JAMA. 2002; 288: 980-987.
34. Lambrinoudaki I, Christodoulakos G, Rizos D, et al. Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur J Endocrinol. 2006; 154: 907-916.
35. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial. J Clin Endocrinol Metab. 2000; 85: 214-218.
36. Mo Q, Lu SF, Simon NG. Dehydroepiandrosterone and its metabolites: Differential effects on androgen receptor trafficking and transcriptional activity. J Steroid Biochem Mol Biol. 2006; 99: 50-58.
37. Haffner SM, Newcomb PA, Marcus PM, Klein BE, Klein R. Relation of sex hormones and dehydroepiandrosterone sulfate (DHEA-SO4) to cardiovascular risk factors in postmenopausal women. Am J Epidemiol. 1995; 142: 925-934.
38. Liu Y, Ding J, Bush TL, et al. Relative androgen excess and increased cardiovascular risk after menopause: A hypothesized relation. Am J Epidemiol. 2001; 154: 489-494.